Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Lerner, Adam | Person |
Why?
|
| Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. | Academic Article |
Why?
|
| PDE4 inhibitors sensitize CLL cells to DNA damage response!mediated apoptosis | Academic Article |
Why?
|
| Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. | Academic Article |
Why?
|
| Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. | Academic Article |
Why?
|
| Preclinical assessment of curcumin as a potential therapy for B-CLL. | Academic Article |
Why?
|
| CRXX-Lerner laboratory CLL Research Collaboration | Grant |
Why?
|
| PDE4 Inhibitors & Glucocorticoids in B-CLL | Grant |
Why?
|
| Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. | Academic Article |
Why?
|
| International consensus statement on the management of cardiovascular risk of Bruton''s tyrosine kinase inhibitors in CLL. | Academic Article |
Why?
|
| Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). | Academic Article |
Why?
|
| Pathology quiz case 1. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) of the LDS. | Academic Article |
Why?
|
| Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. | Academic Article |
Why?
|
| Leshchiner, Ignaty | Person |
Why?
|
| Everett, Peter | Person |
Why?
|